Myeloma
Myeloma
The latest news, research, and perspectives in multiple myeloma. Multiple myeloma is characterized by the proliferation of malignant plasma cells that accumulate in the bone marrow and produce abnormal immunoglobulin. Read more about the pathophysiology, diagnosis, staging, and treatment of myeloma.
Advertisement
Patrick DalyMyeloma | November 29, 2023
Cilta-cel improved survival outcomes compared with standard care in patients with lenalidomide-refractory multiple myeloma.
Read More
Patrick DalyMyeloma | November 29, 2023
Carfilzomib improved PFS versus bortezomib in induction therapy regimens with lenalidomide and dexamethasone in MM.
Patrick DalyMyeloma | November 29, 2023
Lenalidomide-associated ALL was seen in patients with MM, but discontinuation alone led to regression of clonal populations.
Patrick DalyMyeloma | November 28, 2023
Patients with relapsed or refractory multiple myeloma sustained durable remissions after switching to biweekly teclistamab.
Lorinda Coombs, PhD, MSNMyeloma | November 21, 2023
Dr. Coombs discussed the results from a survey of patients with myeloma and APPs who treat myeloma.
Patrick DalyMyeloma | November 16, 2023
Elranatamab was effective and well-tolerated in patients with heavily pretreated relapsed or refractory multiple myeloma.
Advertisement
Melissa BadamoMyeloma | November 15, 2023
Of the 200 APPs surveyed, 72% reported being “generally knowledgeable” about MM before seeing their first patient.
Melissa BadamoMyeloma | November 10, 2023
Getting the right care team, treatment, and testing are three steps to empower patients with MM.
Leah SherwoodPrint | November 10, 2023
Clinicians weigh in on AI advances in hematological diagnoses, prognoses, and treatment.
Magdalena Taube, PhDMyeloma | October 26, 2023
Hematological cancer and death by hematological cancer was reduced in the group that had undergone bariatric surgery.
Blood Cancer TalksBlood Cancer Talks | October 18, 2023
This episode of "Blood Cancer Talks" discusses the biology and management of multiple myeloma and the role of venetoclax.
Cecilia BrownMyeloma | October 16, 2023
The rate of grade 3-5 infections was 90% lower in MM patients receiving IV immunoglobulin than during the observation period.
Sagar Lonial, MD, FACPVideo Insights | October 11, 2023
The panel talks about the future of CAR-T: more targets, sequencing, and other patient considerations.
Patrick DalyMyeloma | October 10, 2023
A study described several mutations and subclone events that appear to drive relapse in multiple myeloma.
Patrick DalyMyeloma | October 10, 2023
Research suggests that "targeting FcRH5 with CAR T cells may represent a promising therapeutic avenue for MM.”
Patrick DalyMyeloma | October 10, 2023
Researchers identified 1,055 patients diagnosed with MM from 2004 to 2018 who underwent AHSCT within a year of diagnosis.
Joseph Mikhael, MDMeeting News | October 10, 2023
Researchers conducted interviews to gather the perspectives of both clinicians and nurses.
Thomas Martin, MDVideo Insights | October 5, 2023
The panel gives their opinions on vaccine strategies for patients with myeloma receiving bispecifics.
Thomas Martin, MDVideo Insights | October 5, 2023
The panel discusses optimal dosing for teclistamab.
Thomas Martin, MDVideo Insights | October 5, 2023
Dr. Martin asks Dr. Chari to provide insights on adverse event management with talquetamab.
Advertisement
Advertisement
Editorial Board